Last reviewed · How we verify
FB825 in intravenous route
At a glance
| Generic name | FB825 in intravenous route |
|---|---|
| Sponsor | Oneness Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults (PHASE1)
- Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis (PHASE2)
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FB825 in intravenous route CI brief — competitive landscape report
- FB825 in intravenous route updates RSS · CI watch RSS
- Oneness Biotech Co., Ltd. portfolio CI